Investigating the Domain Selectivity of Dual Inhibitors of Angiotensin I-Converting Enzyme and Neprilysin

Cardiovascular diseases, driven primarily by hypertension, depend on blood pressure regulation through the renin-angiotensin-aldosterone system (RAAS), endothelin system (ES), and natriuretic peptide and kinin system (NPKS). These pathways require balanced peptide processing by enzymes such as angiotensin-converting enzyme (ACE) and neprilysin (NEP). Current antihypertensive therapies inhibit both the N-domain (nACE) and C-domain (cACE) of ACE, often causing undesirable side effects. To address this, cACE-selective inhibitors have been developed, while simultaneous inhibition of cACE and NEP has demonstrated improved pharmacological efficacy in hypertensive mice. Enzyme kinetic analyses and X-ray crystallography identified three dual cACE/NEP inhibitors (AD017, AD018, and AD019), each exhibiting approximately 10-fold selectivity for cACE over nACE. Notably, AD019 combined this cACE selectivity with low-nanomolar NEP inhibition, making it the most promising lead. These findings demonstrate that hydrophobic P1/P1′ residues and a bulky aromatic P2′ group optimally exploit the hydrophobic subsites of cACE and NEP for drug design.

Authors

Institutions

Publication Details

Journal
Biochemistry
Published
2026-11-18
DOI
https://doi.org/10.1021/acs.biochem.6c00635
Primary Topic
Renin-Angiotensin System Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Investigating the Domain Selectivity of Dual Inhibitors of Angiotensin I-Converting Enzyme and Neprilysin

Gyles E. Cozier, Gregory S. Basarab, Edward D. Sturrock, Charles J. Eyermann et al.
2 links
Biochemistry
Renin-Angiotensin System Studies
article

Investigating the Domain Selectivity of Dual Inhibitors of Angiotensin I-Converting Enzyme and Neprilysin

Gyles E. Cozier, Gregory S. Basarab, Edward D. Sturrock, Charles J. Eyermann, Lauren B. Coulson, K. Ravi Acharya, Kelly Chibale, Sylva L. U. Schwager, Joanna Żukowska
article en

Abstract

Cardiovascular diseases, driven primarily by hypertension, depend on blood pressure regulation through the renin-angiotensin-aldosterone system (RAAS), endothelin system (ES), and natriuretic peptide and kinin system (NPKS). These pathways require balanced peptide processing by enzymes such as angiotensin-converting enzyme (ACE) and neprilysin (NEP). Current antihypertensive therapies inhibit both the N-domain (nACE) and C-domain (cACE) of ACE, often causing undesirable side effects. To address this, cACE-selective inhibitors have been developed, while simultaneous inhibition of cACE and NEP has demonstrated improved pharmacological efficacy in hypertensive mice. Enzyme kinetic analyses and X-ray crystallography identified three dual cACE/NEP inhibitors (AD017, AD018, and AD019), each exhibiting approximately 10-fold selectivity for cACE over nACE. Notably, AD019 combined this cACE selectivity with low-nanomolar NEP inhibition, making it the most promising lead. These findings demonstrate that hydrophobic P1/P1′ residues and a bulky aromatic P2′ group optimally exploit the hydrophobic subsites of cACE and NEP for drug design.

Biochemistry
University of Cape Town (ZA), University of Bath (GB)
Diamond Light Source, UK Research and Innovation, National Research Foundation, South African Medical Research Council, Directorate for Biological Sciences, Biotechnology and Biological Sciences Research Council
Good health and well-being
Renin-Angiotensin System Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon